CMS has released a final regulation on (mostly PRICE) transparency in coverage. See Fed Reg, see Press Release, Fact Sheet. Here, in this blog, see an AI summary.
Meanwhile, the House has posted HR 9393, a bill called Lower Costs, More Transparency Act.
###
AI discusses.
###
The new Transparency in Coverage final rule, announced October 5 and published October 6, improves the usability of health insurers’ price disclosures. CMS’s press release promises clearer information about both what insurance covers and what patients will pay. The operational changes, however, primarily concern price transparency.
The rule updates the 2020 framework for non-grandfathered group and individual health coverage. Insurers must produce smaller, more meaningful machine-readable files: consolidate in-network rates by provider network, remove implausible provider-service combinations, identify networks and insurance products more clearly, and expand available out-of-network payment data. New attestations strengthen accountability for accuracy. In-network and out-of-network files move from monthly to quarterly updates. Personalized cost-sharing information must also be available by telephone. Implementation is phased through 2027.
The business logic is straightforward: enormous, confusing files technically disclose prices without necessarily enabling useful comparisons. (That might be the goal of some stakeholders - block discovery.)
Better data should help employers negotiate, researchers analyze markets, and software developers build shopping tools. Whether patients actually switch providers—and whether prices fall—remains a separate question.
What about coverage transparency? The existing consumer-tool rules already require personalized deductible and cost-sharing information and notification of prerequisites such as prior authorization or step therapy. But they also expressly require a warning that a cost estimate does not guarantee benefits. The new telephone requirement expands access to this information; it does not turn an estimate into a binding coverage determination.
There is also a narrower, genuinely new disclosure: “taxonomy” files expose provider-specialty mappings used to exclude implausible rates, while utilization files identify actual reimbursed provider-service combinations. These illuminate aspects of payment operations, but do not establish a comprehensive public repository of medical-necessity criteria, investigational exclusions, or patient-specific coverage decisions.
Short Compare: HR 9393
H.R. 9393, the bipartisan Lower Costs, More Transparency Act of 2026, pursues closely related goals through legislation. Its introduced text would codify and expand transparency requirements across hospitals, laboratories, imaging providers, ambulatory surgical centers, and health plans. Section 6 closely parallels the rule’s consumer estimates and public pricing files, while adding provisions such as spreadsheet-readable summaries and pharmacy benefit manager spread-pricing disclosures.
The relationship is therefore substantive, but the rule does not implement H.R. 9393: it rests on existing statutory authority. Both initiatives seek to make healthcare markets more understandable and competitive. Neither should be mistaken for a general expansion of covered benefits.
Still, the new HHS final rule partly anticipates H.R. 9393, making portions of 9393 less novel operationally. We see the remaining significance for legislation ini 9393 to grant statutory durability, broader provider obligations, and additional disclosures.
A closer look at H.R. 9393
Representatives Brett Guthrie and Frank Pallone introduced H.R. 9393 on June 23, 2026. The supplied congressional record shows a July 21 committee vote ordering it reported with a substitute, 45–0; the attached legislative text is the introduced version, so the provisions described here should be distinguished from any subsequent substitute.
Much of the bill would take effect in 2028. Hospitals would publish standard charges and consumer-friendly prices for at least 300 shoppable services, where available, with completeness and accuracy attestations. Separate provisions address imaging and ambulatory surgical centers.
For laboratory readers, Section 3 deserves attention. Applicable laboratories receiving Medicare payment would publish discounted cash prices—or gross charges when no cash price exists—for designated tests, including customary ancillary services. They would update prices at least annually and attest to accuracy. Following notice and an opportunity to comply, penalties could reach $300 per day.
Crucially, this provision does not encompass every genomic test: it applies to laboratory tests on CMS’s specified shoppable-services list and expressly excludes statutory advanced diagnostic laboratory tests (ADLTs). That exclusion is narrower than “all advanced molecular diagnostics.”
Section 6 addresses insurers’ negotiated rates, out-of-network payments, personalized estimates, benefit-limit accumulations, and prior-authorization or similar requirements. It also seeks clearer disclosure of PBM spread pricing—the difference between specified amounts charged to the plan and paid to the pharmacy—and annual pricing summaries readable in ordinary spreadsheet software. These are concrete efforts to make disclosed information easier to interpret and use.
##
Update! Does this week's final rule cast light on updates for HR9393?
Yes—the HHS regulationi increases the overlap and reduces the incremental impact of some H.R. 9393 provisions. The final rule already advances several of the bill’s goals: more usable pricing files, reduced duplication, stronger accountability, and telephone access to personalized estimates.
But the bill still adds substance. It would place requirements directly into statute, extend explicit disclosure obligations to laboratories, imaging providers, and ambulatory surgical centers, and add provisions such as spreadsheet-readable summaries and PBM spread-pricing disclosures.
For your blog: “The final rule partly anticipates H.R. 9393, making portions less novel operationally. The bill’s remaining significance lies in statutory durability, broader provider obligations, and additional disclosures.”
That comparison is to the introduced bill text supplied, rather than the committee substitute.
Source documents: 2026 CMS 1005 Press release on TRANSpARENT COVERAGE.pdf 2026 HHS CMS 1006 (price) Transparency in coverage 120p.pdf 2026 HILL HR 9393 Transparency Coverage ETc ACT.pdf
